No convincing evidence prompts NICE no to Celgene's Revlimid
This article was originally published in Scrip
Executive Summary
Celgene has, for now, failed to convince NICE, the health technology appraisal body for England and Wales to recommend its Revlimid (lenalidomide) for patients with myelodysplastic syndromes. Although it acknowledged the drug's benefits, like reduced time in hospital and need for transfusions, the institute was unconvinced that the drug actually extends lives.